Skip to content

Advertisement

Volume 18 Supplement 2

Sepsis 2014

  • Poster presentation
  • Open Access

Immunomodulation and infection: identification of small molecule TLR3 blockers to combat deleterious inflammation in pneumonia

  • F Sônego1,
  • B Pouzet1,
  • F Pecceu2,
  • L Leotard1,
  • B Martin1,
  • P-E Rouby1,
  • L Goullieux1,
  • C Ravinet-Trillou1,
  • J-M Bras3 and
  • C Serradeil-Le Gal1
Critical Care201418(Suppl 2):P55

https://doi.org/10.1186/cc14058

Published: 3 December 2014

Keywords

Human Lung Epithelial CellHuman TLR3Small Molecule LibraryPotent Small MoleculeSmall Molecule Probe

Introduction

Pneumonia is a common cause of death worldwide and the leading cause of sepsis and shock in the ICU. Controlling excessive immune stimulation with deleterious consequences for the host organs is a major strategy in severe infections. In addition to viral dsRNA, the immune Toll-like receptor 3 (TLR3) senses RNA released from injured tissues and necrotic cells promoting excessive inflammatory cytokine release in pulmonary epithelial, endothelial and immune cells. Thus, as a potent regulator of the lung immune response, TLR3 represents a specific target to control damaging inflammation in severe lung infections in combination with antimicrobials. Here, we aimed to characterize potent small molecules displaying in vitro and in vivo TLR3 blocker activities and develop several preclinical models to investigate the role of TLR3 in pneumonia.

Results

We identified compounds with anti-TLR3 activity (IC50 = 50 nM) through random screening and structure-activity relationship analysis by testing small molecule libraries on recombinant hTLR3-HEK293 cells. Selected compounds interacted with mouse and human TLR3, were devoid of effect on TNFα-induced activation at 1 µM on HEK293 cells and exhibited good early-ADME properties. Hit molecules also counteracted PolyAU (PAU)/Poly(I:C) (PIC)-induced cytokine release (IL6, IL8, IP-10) on human bronchial epithelial cells (BEAS-2B) expressing native TLR3 receptors. Interestingly, sustained stimulation of BEAS-2B by PAU/PIC (0.1 to 10 µM) to mimic viral activation induced overexpression of TLR3 mRNA, which was dose-dependently inhibited by these compounds, as evidenced by RT-qPCR. In vivo, we confirmed the anti-TLR3 activity (3 to 30 mg/kg i.p.) against PAU/PIC (100 µg/mouse i.v.) but not flagellin-induced plasma cytokine release in CD1 mice. To study these TLR3 inhibitors under pathological situations, we developed models of Streptoccocus pneumoniae (ATCC6303) or Pseudomonas aeruginosa (PAO-1)-induced pneumonia post influenza A virus (IAV PR/8/34 H1N1) infection. Mice previously challenged with intranasal IAV showed enhanced susceptibility to lung bacterial infections with a dramatic mortality rate, whereas separately these pathogens are not lethal. In addition, IAV/S. pneumoniae co-infected mice showed increased lung and blood bacterial loads with severe inflammation signs evidenced by elevated systemic IL-6 and KC levels and important lung tissue damages. Currently, TLR3 blockers are ongoing evaluation in these models.

Conclusion

Immunomodulation and personalized treatments are becoming relevant approaches to manage severe infections. Here, we discovered the first small molecule probes targeting mouse and human TLR3. These compounds efficiently control TLR3-triggered proinflammatory response in vitro and in vivo and shape TLR3 overexpression in human lung epithelial cells. They represent valuable pharmacological tools to study the contribution of TLR3 in pneumonia and to propose new adjuvant immunotherapies.

Declarations

Acknowledgements

The research leading to these results has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013/ under REA grant agreement number 316682.

Authors’ Affiliations

(1)
Sanofi TSU ID, Toulouse, France
(2)
SCP LGCR, Toulouse, France
(3)
Biologics, Toulouse, France

Copyright

© Sônego et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement